Blog
RSS FeedPosted by Michael Wonder on 05 Sep 2016
Xultophy (insulin degludec/liraglutide) receives European approval for use in adults with type 2 diabetes mellitus and moderate renal impairment
1 September 2016 - Novo Nordisk has announced that the European Commission has approved the expanded use of Xultophy (insulin degludec ...
Posted by Michael Wonder on 27 Jul 2016
EMA publishes EPAR for Qtern (saxagliptin hydrochloride with dapagliflozin propanediol monohydrate)
27 July 2016 - The EMA has published an EPAR for AstraZeneca's Qtern. ...
Posted by Michael Wonder on 20 Jul 2016
AstraZeneca receives approval in the EU for Qtern (saxagliptin and dapagliflozin) for treatment of type 2 diabetes mellitus
19 July 2016 - AstraZeneca today announced that the European Commission has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type ...
Posted by Michael Wonder on 27 May 2016
Highlights from the CHMP 23-26 May 2016 meeting
27 May 2016 - Six medicines, including two combination therapies for chronic hepatitis C, recommended for approval. ...